Timely diagnosis of cirrhosis and HCC surveillance using ultrasound may help improve patient outcomes
Hepatocellular carcinoma (HCC) is an important cause of cancer death in Australia (Box 1). A 2019 report on cancer in Australia, based on data from 1982 to 2015, showed that liver cancer (90% HCC) had the second largest increase (378%) in age‐standardised incidence rates from 1.8 to 8.6 per 100 000 population.1 Unfortunately, there was a matching threefold increase in liver cancer mortality rate from 2.3 deaths to 7.0 per 100 000 population. This was the largest increase for any cancer and, unlike other cancers, is likely an underestimate owing to under‐reporting by some state cancer registries.2 An Australia‐wide epidemiological study found survival from HCC had improved from a median of 2.1 months (95% CI, 1.6–2.6 months) between 1982 and 1984 to 12.1 months (95% CI, 11.2–13.0 months) between 2010 and 2014 (P < 0.001).3 However, survival remains poor and HCC is the only low survival cancer of all the cancers that are rapidly increasing in incidence in Australia.1 The average cost to treat HCC is $50 000 and liver transplantation costs $166 000.4,5 Therefore, with incidence showing no signs of slowing, health system costs will continue to increase substantially in the absence of preventive actions. This article reviews the present evidence for liver ultrasound surveillance in patients with cirrhosis, a major risk factor for the development of HCC.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Institute of Health and Welfare. Cancer in Australia 2019 (Cancer Series No. 119; Cat. No. CAN 123). Canberra: AIHW, 2019. https://www.aihw.gov.au/getmedia/8c9fcf52-0055-41a0-96d9-f81b0feb98cf/aihw-can-123.pdf.aspx?inline=true (viewed Feb 2020).
- 2. Hong TP, Gow P, Fink M, et al. Novel population‐based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. Hepatology 2016; 63: 1205–1212.
- 3. Wallace MC, Preen DB, Short MW, et al. Hepatocellular carcinoma in Australia 1982‐2014: increasing incidence and improving survival. Liver Int 2019; 39: 522–530.
- 4. McElroy HJ, Roberts SK, Thompson AJ, et al. Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study. J Med Econ 2017; 20: 72–81.
- 5. Independent Hospital Pricing Authority. National Hospital Cost Data Collection Report, Public Sector, Round 21 (Financial year 2016‐17). Sydney: IHPA, 2019. https://www.ihpa.gov.au/publications/national-hospital-cost-data-collection-report-public-sector-round-21-financial-year (viewed Aug 2019).
- 6. Huang Y, Joseph J, de Boer WB, et al. Long‐term liver‐related outcomes of patients with chronic liver diseases in Australia. Clin Gastroenterol Hepatol 2020; 18: 496–504.
- 7. Powell EE, Skoien R, Rahman T, et al. Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians. EClinicalMedicine 2019; 11: 44–53.
- 8. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust 2016; 204: 268–272. https://www.mja.com.au/journal/2016/204/7/australian-recommendations-management-hepatitis-c-virus-infection-consensus.
- 9. Ronot M, Pommier R, Dioguardi Burgio M et al. Hepatocellular carcinoma surveillance with ultrasound—cost‐effectiveness, high‐risk populations, uptake. Br J Radiol 2018; 91: 20170436.
- 10. Huang Y, Wallace MC, Adams LA, et al. Rate of nonsurveillance and advanced hepatocellular carcinoma at diagnosis in chronic liver disease. J Clin Gastroenterol 2018; 52: 551–556.
- 11. Bertot LC, Jeffrey GP, Wallace M, et al. Nonalcoholic fatty liver disease‐related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun 2017; 1: 53–60.
- 12. Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost‐effectiveness analysis in France and in the United States. Hepatology 2017; 65: 1237–1248.
- 13. Singal A, Volk ML, Waljee A, et al. Meta‐analysis: surveillance with ultrasound for early‐stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37–47.
- 14. Sato T, Tateishi R, Yoshida H, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009; 3: 544–550.
- 15. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta‐analysis. PLoS Med 2014; 11: e1001624.
- 16. Hong TP, Gow PJ, Fink M, et al. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population‐based study. Med J Aust 2018; 209: 348–354. https://www.mja.com.au/journal/2018/209/8/surveillance-improves-survival-patients-hepatocellular-carcinoma-prospective.
- 17. Chinnaratha MA, Campbell K, Mathias R, et al. Improved survival of hepatocellular carcinoma patients diagnosed with a dedicated screening programme – a propensity score adjusted analysis. J Gastrointest Cancer 2019; 50: 888–893.
- 18. Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology 2017; 65: 1196–1205.
- 19. Zhao C, Xing F, Yeo YH, et al. Only one‐third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta‐analysis. Eur J Gastroenterol Hepatol 2020; 32: 406–419.
- 20. Weis A, Marquart L, Calvopina DA, et al. Serum microRNAs as biomarkers in hepatitis C: preliminary evidence of a microRNA panel for the diagnosis of hepatocellular carcinoma. Int J Mol Sci 2019; 20: pii: E864.
No relevant disclosures.